viruses in combination with neoantigens are potent stimulators of an immune response and therefore make excellent adjuvants.'
This research led to the development of the AD-MSC based platform technology which incorporates three important elements: (i) The ability to protect oncolytic
viruses from complement inactivation and innate immune cell inactivation; (ii) The ability to support oncolytic
viral amplification in the AD-MSC, and (iii) The ability to modify tumor microenvironment by inducing transient immune suppression to allow effective tumor cell targeting and viral amplification at the tumor site for an extended period of time.
viruses that can selectively replicate in and lyse cancer cells without harming normal cells are qualified enough to become a powerful platform for immunotherapy involving both direct tumor cell lysis and the induction of immunogenic cell death (ICD).
New report package "Immunotherapy with Oncolytic
Viruses and mRNA Vaccines & Therapeutics" (available at http://bit.ly/2BmZFyG) drawn up by La Merie Publishing offers an up-close look at the global immunotherapy landscape, with a focus on oncolytic
viruses and mRNA vaccines and therapeutics.
Transgene previously reported a preclinical proof-of-concept data showing that an oncolytic
Vaccinia virus encoding a sequence of anti-PD1 demonstrated better overall survival than the combination of separate single agents.
Evidence suggests that the host immune response seems to reduce the effectiveness of oncolytic
viruses and their specific targeting to tumour cells.
viruses (OVs) have been recently recognized as an effective treatment for cancer in preclinical models and promising clinical responses in human cancer patients .
Mathematical models have been applied to the understanding of oncolytic
virotherapy since fifteen years ago.
The use of cell carriers to deliver oncolytic
viruses to primary tumors and metastases addresses many of these obstacles.
viruses are novel multifunctional anticancer agents with increasingly promising outcomes in patients .
viruses, with their long history of experimentation, have been deemed to be a key player in the future treatment of gliomas.